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[571 ABSTRACT 
Structurally altered capsular polysaccharides are pro- 
duced by mutant bacteria. These polysaccharides are 
isolated by selecting a wild type bacterial strain and a 
phage producing degradative enzymes that have sub- 
strate specificity for the capsular polysaccharides pro- 
duced by the wild type bacteria. Phage-resistant mu- 
tants producing capsular polysaccharides are selected 
and the structurally altered capsular polysaccharide is 
isolated therefrom. 
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The invention described herein was made in the per- 
formance of work under a NASA contract, and is sub- 
ject to the provisions of Public Law 96-517 (35 U.S.C. 
Q 202) in which the Contractor has elected to retain 
title. 10 
This application is divisional of U.S. Ser. No. 
07/799,419 filed Nov. 27, 1991, now U.S. Pat. No. 
5,3 30,903. 
This invention relates to novel and useful complex 
polysaccharides and methods for producing them. 15 
More particularly, this invention relates to structurally 
altered capsular polysaccharides produced by bacterial 
mutants. 
BACKGROUND OF THE INVENTION 2o 
Complex polysaccharides have a variety of industrial 
applications. Generally these molecules alter the physi- 
cal properties-including viscosity and rheology-of 
fluid media in which they are suspended. Accordingly, 
complex polysaccharides are used as thickeners in the 25 
food industry, for suspending waste fragments in dril- 
ling or cutting operations, and as water soluble lubri- 
cants. Baird et al., “Industrial Applications Of Some 
New Microbial Polysaccharides,” Biotechnology, No- 
vember 1983, pp. 778-83. For similar reasons, complex 
polysaccharides are also used to reduce turbulence of 
fluid flow in pipelines and other containers. J. W. Hoyt, 
Drag Reduction In Polysaccharide Solutions, Trends In 
Biotechnology, 3, 17-20 (1985). The physico-chemical 
basis for these effects is not understood, id. although 
correlations between drag reduction and the extensional 
viscosity of polysaccharides have been reported. G. R. 
Petersen et al., “Rheologically Interesting Polysaccha- 
rides From Yeasts”, Appl. Biochem. Biotech., 20/21, 
845-67 (1989). 
Because the basis for these useful properties of com- 
plex polysaccharides is not understood, the identifica- 
tion of useful complex polysaccharides requires screen- 
ing of candidate polymers. Accordingly, it is desirable 
to develop methods for producing new candidate com- 
plex polysaccharides for evaluation. 
SUMMARY OF THE INVENTION 
Structurally altered capsular polysaccharides are 
produced by mutant bacteria. These polysaccharides 
are isolated by selecting a wild type bacterial strain and 
a phage producing degradative enzymes that have sub- 
strate specificity for the capsular polysaccharides pro- 
duced by the wild type bacteria. Phage-resistant mu- 
tants producing capsular polysaccharides are selected 
and the structurally altered capsular polysaccharide is 
isolated therefrom. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The cells of many bacterial species-specifically, 
gram positive bacteria-are surrounded by a glycocalyx 
also referred to as a capsular polysaccharide (“CPS”) 
several hundred nanometers in thickness. The glycoca- 
1 yx consists of a complex polysaccharide polymer that 
appears to be species specific. H. Geyer et al. “Degrada- 
tion Of Bacterial Surface Carbohydrates By Virus- 
Associated Enzymes”, Pure And Applied Chemistq 55, 
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pp. 637-53 (1983). Hence bacteria have proved to be an 
important source of complex polysaccharides. Baird et 
al. (1983). Bacteria are an especially desirable source of 
polysaccharides because of the purity and uniformity of 
the product. 
Bacteriophage are viruses that infect bacteria. The 
viruses that infect bacteria encapsulated by a glycoca- 
lyx are specially adapted to penetrate the polysaccha- 
ride barrier. The tail fibers or spikes by which these 
viruses are seen to attach to bacteria contain en- 
zymes-generally referred to as endoglycanases or en- 
dopolysaccharases-that degrade the glycocalyx. 
These enzymes exhibit a high degree of substrate speci- 
ficity. Geyer et al, supra at pp. 38-39. 
According to the present invention, a strain of encap- 
sulated bacteria and the specific phage which infects it 
are employed. The selected bacteria are optionally ex- 
posed to a mutagenic agent. Examples of useful muta- 
genic agents include radiation and chemical mutagens, 
such as nitrosoguanidine. The mutagenized bacterial 
cells are grown to a desired density, and then screened 
for resistance to phage that specifically degrade the 
glycocalyx of the wild type strain. Surviving bacteria 
are likely to have a glycocalyx with altered chemical 
structure. The CPS of the selected bacterial strains is 
harvested with enzymes derived from phage. The iso- 
lated CPS is purified by known techniques and de- 
graded to oligomer by further treatment with phage 
enzymes. 
In one embodiment of the present invention, we em- 
ployed a strain Klebsiella pneumoniae that produces a 
capsular polysaccharide known as K63, and a phage 
(“K63 phage”) that specifically degrades the same poly- 
saccharide. We obtained Klebsiella pneumoniae strain 
5845/52 from the World Health Organization. This 
strain produces the K63 capsular protein. The K63 CPS 
is a straight chain heteropolymer of fucose, galacuronic 
acid and galactose, linked, in that order by a 1-3 glyco- 
sidic linkages. The K63 phage enzymatically hydro- 
lyzes the a 1-3 linkage between the galactose and fu- 
cose monomers. Both the nature of the CPS polymer 
and the mode of action of the K63 phage enzyme are 
representative, and support the general applicability of 
our method. 
We selected mutants for further study that were ei- 
ther spontaneously generated or were induced by expo- 
sure to the mutagenic agents nitrosoguanidine or ultra- 
violet radiation. J. H. Miller, Experiments In Molecular 
Genetics (1972). Following treatment to induce muta- 
tion, cells were grown on DIFCO Nutrient Broth, sup- 
plemented with 1% glucose, at 30” C., while rotated at 
150 rpm. Cells were grown to early stationary phase 
(OD590 of approximately 3.5). Calcium chloride (0.1M) 
was added to stabilize the CPS matrix. 
The fresh stationary phase culture, less than 2 hours 
old, contained approximately 2.5 X 109 viable cells/mi. 
Phage 63 was added at a concentration sufficient to 
achieve a multiplicity of infection (“MOI”) of between 
one and five. The culture was incubated at room tem- 
60 perature for about 10 minutes to permit phage to attach 
to the bacterial cells. The infected culture was then 
diluted 10 fold into fresh glucose supplemented nutrient 
broth and grown overnight to stationary phase. 
Phage resistant mutants were isolated as single colo- 
65 nies on petri dishes after streaking with the overnight 
culture of infected bacteria. Resistant colonies that did 
not form plaques were selected. Phage resistance of the 
selected colonies was confirmed by administration of a 
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drop of phage/enzyme concentrate. The zone of lysis two points, 12.7 cm apart, along a 1 mm pipe. Between 
produced by the diffusion of the phagelenzyme concen- sample runs, the rheometer was rinsed with tap water 
trate was dramatically reduced for those strains with until the baseline returned to normal. Sample size was 
phage resistance when compared with wild type hac- 100 ml and all measurements were made with water as 
the solvent. Sample observations were normalized teria. 
(wt/ppm or mgA) typically 100-500 wt/ppm. Our ob- Mutants whose phage resistance was due to altered CPS were selected from among those phage resistant 
mutants already identified. The phage resistant colonies servations were reproducible to within 1-2%. We con- 
were grown for to days so that mucoid ( c p ~  pro- sidered measurements that differed by less than 5% to 
ducing) and non-mucoid mutant colonies could be dis- 10 be 
tinguished, The colonies were retested for phage psis- Our observations Of drag reduction Coefficients for 
tance as before. Mucoid mutants that remained phage wild type and mutant cps (from 8 mutant strains) are 
resistant were assumed to have altered CPS. Non- summarized in Table 1. Mutant strains 1, 2 and 5 were 
mucoid phage resistant mutants were assumed to be spontaneous mutants, while strains 3,4, 5,6, and 8 were 
resistant for other reasons, for example, lacking virus 15 induced by nitrosoguanidine. All mutants showed a 
receptor sites. Approximately 90% of the 5845152 decrease in pyruvulation while altered NMR spectra 
Phage resistant mutants have altered cps by this trite- have been detected only in the spontaneous mutants. 
rion. Our results show a 10% improvement in drag reduction 
cps from in the CPS from mutant bacteria. Furthermore, as also 
mutant cells to affect rheological properties of aqueous 20 shown in Table 1, cps from mutant bacteria is 
mutant bacterial cells, like those produced by large- 
scale industrial fermentations, is resistant to high speed 
centrifugation. We succeeded in achieving substantial 
purification of the altered CPS using a concentrated 25 
extract of phage enzymes. 
In Order to test the capacity Of the 
media? we partially purified the cps. The resistant to mechanical shearing as determined by re- 
peated observations of drag reduction with a rheome- 
ter. 
TABLE 1 
Characterization of K63 CPS Mutants: 
Drag Reduction Results A concentrated mixture of CPS specific enzyme and 
phage fragments was prepared by preparing a phage 
lysate from stationary phase cultures, and concentrating STRAIN REDUCTION STABILITY 
55.9 84.9 
(HPI lo), followed by dialysis to remove low molecular K63-JPLI 67.7 95.6 
weight substances. The final concentration factor was K63-JPL2 66.7 95.6 
enzymatic activity as determined by a reducing end K63-JPL4 67.6 98.2 
67.0 99.4 K63-JPL5 
35 K63-JPL6 67.6 95.7 
K63-JPL8 67.2 99.7 
% SHEAR % DRAG 
the lysate 80 fold with an AMICON hollow fiber filter 3o 
39. This material showed a 24-fold enhancement in K63-JPL3 67.0 99.4 
sugar assay, as compared with crude phage lysate. 
Phage/enzyme concentrate was added in small quan- 
tities-I ml/liter-to cultures of mutant bacterial cells. 
This results in a rapid and dramatic reduction (> 100 
fold) in the viscosity of the culture media. Altered CPS While we have presented a number of embodiments 
was thereafter separated from the bacterial cells by low 4o of this invention by way of examples, it is apparent that 
speed centrifugation at 20" c. Immediately after centrif- our basic construction can be altered to provide other 
ugation, the supernatant was Precipitated by the embodiments that also employ our invention. The scope 
tion of 4 volumes ofisoProPanol at -20" c. We have of our invention is defined by the scope of the claims, 
resulting precipitate was rehydrated and extensively 45 be illustrative. 
dialyzed against deionized water. 
The CPS polymer obtained from wild-type K63 bac- 
teria had an apparent molecular weight of 3.5X106 
daltons. Digestion of this material with phage 63 en- 
perse polysaccharide with a molecular weight of 50 
9.0X 105 daltons. 
We measured the drag reduction produced by undi- 
gested CPS harvested from wild type and mutant K63 
bacteria using a turbulent flow rheometer fabricated 
according to the design of Hoyt [J. W. Hoyt, Polymer 55 
Letts., 9,85 1-62 (1971); J. W. Hoyt, "The solution Prop- 
erties Of natural Polymers", The Chemical society SPe- 
ciul Publication, No. 23, (London) pp. 86-91 (1968)l 
63 Wf 
in place Of isopropanol. The rather than by the examples, which are only intended to 
We claim: 
1. An isolated altered capsular polysaccharide pro- 
duced by the steps Of: 
zyme reproducibly yielded a homogeneous mono-dis- (a) providing a wild type bacterial strain that pro- 
duces a capsular polysaccharide and a bacterio- 
phage that degrades at least one capsular polysac- 
charide produced by the wild type bacterial strain; 
(b) selecting phage resistant mutants of the bacterial 
strain that produce a capsular polysaccharide; 
(c) propagating mutants to obtain a culture thereof; 
and 
(d) harvesting the'altered capsular polysaccharides of 
the mutants. 
modified by altering Pipe diameter to operate at a fixed 
calculated: 
2. The isolated altered capsular polysaccharide of 
Reynolds number of 16,500. The drag reduction was 6o claim 1 wherein the wild type bacterial strain is Klebsj- 
elIa pneumoniae 5845/82. 
3. The isolated altered capsular polysaccharide of 
claim 1 wherein the capsular polysaccharide is K63. 
4. The isolated altered capsular polysaccharide of 
claim 1 wherein the step of selecting mutants optionally 
comprises the step of treating the selected wild type 
bacterial strain with a mutagenic agent. 
Drog Reduction 
(%I= 100 X (p&/wn- ~ D , s " / ~ I ; ~ , ~ ) / ~ ~ ~ ~ / ~ ~ , , , ,  
65 
Where PDsoivenl and PDso/ution are the pressure differ- 
ences in the solvent and solution, respectively, mea- 
sured from a strip chart recording of pressures taken at 
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5. The isolated altered capsular polysaccharide of 
claim 1 wherein the mutagenic agent is radiation or 
nitrosoguanidine. 
6. The isolated altered capsular polysaccharide of 
claim 1 Wherein the step of selecting mutants further 
comprises the steps of: 
(a) exposing bacterial cultures to degradative phage 
enzymes with substrate specificity for the capsular 
polysaccharide of the wild type bacterial strain; 
and 
polysaccharide but survive exposure to the de- 
gradative phage enzyme of step (a) above. 
7. The isolated altered capsular polysaccharide of 
claim 1 wherein the step of harvesting further comprises 
the steps of: 
(a) treating the mutant bacterial cultures with phage 
enzyme; 
(b) separating the capsular polysaccharide from other 
components of the treated mutant bacteria by cen- 
trifugation; and 
(C) Precipitating the supernatant obtained in step (b) 
above with cold isopropanol or cold ethanol. 
8. The isolated altered capsular polysaccharide of 
claim 7, wherein the step of separating further com- 
trated phage enzyme. 
10 
(b) selecting those that produce a capsular prises the step of digesting the precipitate with concen- 
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